$1.30
0.76% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Stock price

$1.30
+0.00 0.00% 1M
-1.62 55.48% 6M
-0.16 10.96% YTD
-12.62 90.66% 1Y
-624.80 99.79% 3Y
-10,741.74 99.99% 5Y
-2,460,056.30 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 0.76%
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Key metrics

Market capitalization $4.12m
Enterprise Value $2.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.15
P/S ratio (TTM) P/S ratio 4.12
P/B ratio (TTM) P/B ratio 6.13
Revenue growth (TTM) Revenue growth 978.39%
Revenue (TTM) Revenue $1.00m
EBIT (operating result TTM) EBIT $-13.77m
Free Cash Flow (TTM) Free Cash Flow $-11.62m
Cash position $2.06m
EPS (TTM) EPS $-12.83
P/S forward 4.12
EV/Sales forward 2.15
Short interest 4.09%
Show more

Is Sonnet BioTherapeutics Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:

Buy
100%

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1 1
1,011% 1,011%
100%
- Direct Costs 0.09 0.09
13% 13%
9%
0.91 0.91
9,000% 9,000%
91%
- Selling and Administrative Expenses 8 8
43% 43%
800%
- Research and Development Expense 6.60 6.60
3% 3%
660%
-14 -14
10% 10%
-1,368%
- Depreciation and Amortization 0.09 0.09
13% 13%
9%
EBIT (Operating Income) EBIT -14 -14
10% 10%
-1,377%
Net Profit -13 -13
58% 58%
-1,329%

In millions USD.

Don't miss a Thing! We will send you all news about Sonnet BioTherapeutics Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral
GlobeNewsWire
20 days ago
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6 th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.
Neutral
GlobeNewsWire
about one month ago
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010
Neutral
GlobeNewsWire
about 2 months ago
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )
More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office United States
CEO Raghu Rao
Employees 13
Founded 2011
Website www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today